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Background: There has been a shift towards greater use of neuraxial over general anaesthesia for patients
undergoing total hip or knee arthroplasty. Furthermore, suggestions that peripheral nerve block may reduce
adverse effects have recently been put forward. Although older studies showed a reduction in venous
thromboembolism (VTE) with neuraxial compared with general anaesthesia, this difference has not been confirmed
in studies using effective current thromboprophylaxis. We used a large data set to investigate the pattern of
anaesthesia usage, and whether anaesthesia type affects efficacy and bleeding outcomes of thromboprophylaxis
overall, within each treatment group, or for the novel oral anticoagulant dabigatran etexilate versus enoxaparin.
Methods: Three previously reported trials compared 220 mg and 150 mg dabigatran etexilate once daily with
enoxaparin after knee or hip arthroplasty. A pooled analysis was performed in patients receiving general or
neuraxial anaesthesia, or the combination of either with peripheral nerve block (n = 8062). Outcome measures were
major VTE plus VTE-related mortality, major bleeding and major plus clinically relevant bleeding events.
Results: General, neuraxial and combination anaesthesia were used in 29%, 52% and 19% of patients, respectively.
Differences in efficacy and safety between anaesthesia subgroups were small and not significant, except for a
slightly higher rate of major VTE and VTE-related mortality with general versus neuraxial anaesthesia (odds ratio:
1.40; 95% confidence interval: 1.03–1.90; p = 0.035) in the overall population. There were no significant effects of
anaesthesia type on efficacy or safety of dabigatran etexilate versus enoxaparin.
Conclusions: Anaesthesia type did not greatly affect efficacy and safety outcomes in the pooled population of all
three treatment groups. The efficacy and safety of dabigatran etexilate was comparable with enoxaparin, regardless
of type of anaesthesia.
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Patients undergoing total hip or knee arthroplasty sur-
gery are known to be at high risk of venous thrombo-
embolism (VTE) [1] and hence thromboprophylaxis is
recommended [2]. To date, low molecular weight hep-
arin (LMWH) has been most frequently used to prevent
VTE following orthopaedic surgery [3], but this therapy
is administered subcutaneously. To optimize patient
care, research into new anticoagulants has concentrated
on oral therapies.
Dabigatran etexilate is a new, reversible, oral direct
thrombin inhibitor that has been approved in many
countries worldwide for use in orthopaedic surgery [4].
Three pivotal Phase III clinical trials – RE-MODEL™,
RE-NOVATEW and RE-MOBILIZEW – investigated the
efficacy and safety of 220 mg and 150 mg dabigatran
etexilate once daily compared with subcutaneous enoxa-
parin as thromboprophylaxis in patients undergoing
total hip or knee arthroplasty [5-7].
In recent years there has been a shift in the anaesthe-
sia techniques used in orthopaedic surgery, from general
to regional anaesthesia. A study by Anderson et al.
shows that, in 1996, 35% of patients undergoing total
hip arthroplasty and 43% undergoing total knee arthro-
plasty received spinal or epidural anaesthesia, while in
2001 these figures had increased to 46% and 54%, re-
spectively [8]. In addition, peripheral nerve blocks are
being increasingly used during hip and knee arthroplasty
[9], and may represent the future trend.
With all anticoagulants, a major consideration is the
balance between efficacy (prevention of VTE) and safety
(mainly bleeding). Available evidence suggests that neur-
axial anaesthesia lowered the rate of VTE compared
with general anaesthesia in studies conducted before the
widespread use of effective anticoagulation; but now that
patients are given appropriate, risk-adjusted thrombo-
prophylaxis with newer agents, this difference no longer
exists [10]. However, a recent review of randomized con-
trolled trials since 1990 (18 studies involving 1239
patients) concluded that there was insufficient evidence
to determine whether anaesthetic technique influenced
mortality, cardiovascular morbidity or the incidence of
VTE when using thromboprophylaxis [11].
The following studies of dabigatran in major ortho-
paedic surgery provide a large data set (8062 patients): the
study of thromboembolism prevention after knee surgery
(RE-MODEL™), the study of extended thromboembolism
prevention after hip surgery (RE-NOVATEW) and the
study of thromboembolism prevention after knee surgery
(RE-MOBILIZEW). Here we report the pattern of anaes-
thesia usage and the results of three post-hoc analyses to
determine (a) whether the type of anaesthesia affects effi-
cacy and safety outcomes in the context of contemporary
patient management and thromboprophylaxis modalitiesin the overall study population, regardless of treatment as-
signment, (b) whether there was any impact of anaesthetic
technique on the efficacy and safety of dabigatran relative
to enoxaparin and (c) whether anaesthetic technique influ-
enced efficacy and safety within each treatment group.
Methods
Trial designs
All trials were performed in compliance with the Declar-
ation of Helsinki (1996) and the International Confer-
ence on Harmonisation (ICH) Harmonised Tripartite
Guideline for Good Clinical Practice and in accordance
with applicable local and national regulatory require-
ments. All patients provided written informed consent.
The clinical trial protocols were reviewed by the ethics
committees/institutional review boards of the coordinat-
ing investigators and all principal investigators of the
participating centres. The EudraCT numbers were as
follows: for RE-MODEL™, 2004-001317-34 (17 June
2004); for RE-NOVATEW, 2004-001988-21 (20 July
2004) for RE-MOBILIZEW, 2005-001998-10 (28 April
2005).
Full details of the three prospective, double-blind,
double-dummy, randomized, multicentre, non-inferiority,
pivotal trials have been reported previously [5-7]. Briefly,
the European trials, RE-MODEL™ (NCT00168805) and
RE-NOVATEW (NCT00168818), compared 220 mg and
150 mg once daily dabigatran etexilate (Boehringer
Ingelheim International GmbH, Ingelheim am Rhein,
Germany) with 40 mg once daily subcutaneous enoxa-
parin (Clexane, Klexane or Lovenox; Sanofi-Aventis,
Paris, France), following knee or hip arthroplasty, re-
spectively. Patients aged over 18 years were randomized
the day before surgery using a computer-generated
scheme. As these were double-blind trials, all patients
received two oral capsules in the morning and a sub-
cutaneous injection in the evening. The injection regime
was generally initiated the evening before surgery, al-
though in some countries it was initiated post-
operatively. Dabigatran etexilate treatment was initiated
as a half-dose 1–4 hours after the completion of sur-
gery, followed by the full dose the next day. Patients
were treated for 6–10 days in the RE-MODEL™ trial
and for 28–35 days in RE-NOVATEW. All patients were
to undergo bilateral venography, which was assessed
centrally by the independent adjudication committee,
within 24 hours of the last dose [5,6].
The RE-MOBILIZEW trial (NCT00152971) assessed
patients undergoing knee arthroplasty. To reflect North
American practice, patients were randomized after sur-
gery to 220 mg or 150 mg dabigatran etexilate once
daily, or 30 mg subcutaneous enoxaparin twice daily.
Patients received oral capsules and an injection in the
morning, followed by a second injection in the evening.
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while dabigatran etexilate was initiated as a half dose 6–
12 hours after surgery. Patients received treatment for
12–15 days and were to undergo bilateral venography
(which was assessed centrally) within 12 hours of the
last dose [7]. In each trial, an independent expert adjudi-
cation committee assessed the outcomes.
The three trials were designed to be as similar as pos-
sible to enable the prospectively defined meta-analyses.
Thromboprophylaxis could be continued after termin-
ation of the study at the discretion of the treating phys-
ician and all patients attended a follow-up visit 3 months
after surgery. Concomitant treatment with aspirin at
doses <160 mg and with selective cyclooxygenase-2
inhibitors was permitted, as was the use of elastic com-
pression stockings; use of intermittent pneumatic com-
pression devices was not permitted. In addition, the
main exclusion criteria in all three trials excluded
patients with a history of bleeding diatheses, a coagula-
tion disorder, creatinine clearance <30 mL/min, or who
had undergone ≥3 attempts to place spinal or epidural
anaesthesia or in whom the placement was traumatic.
Outcome measures
The primary efficacy outcome in all trials was total VTE
(symptomatic or venographic deep vein thrombosis
[DVT], and/or symptomatic pulmonary embolism) and
all-cause mortality, as agreed with the authorities during
the planning process for the studies. However, this end-
point was not suitable for the post-hoc analysis due to
the heterogeneity of the trials resulting from differences
in the type of operation (hip versus knee arthroplasty),
enoxaparin regimen used, timing of initiation of therapy
and the duration of therapy. Hence the efficacy endpoint
used in these pooled analyses was the composite of
major VTE (venographic or symptomatic proximal DVT
and/or pulmonary embolism) and VTE-related mortality
during treatment. This was a secondary endpoint in the
individual studies due to limitations regarding power
and sample size. However, it was pre-specified for the
meta-analyses, is more clinically relevant than total VTE
and all-cause mortality, and is currently recommended
by the European regulatory authorities as the primary
endpoint for therapeutic non-inferiority of VTE preven-
tion [12]. Ventilation-perfusion scintigraphy, pulmonary
angiography, spiral chest computer tomography or aut-
opsy determined the presence of pulmonary embolism.
Compression ultrasound or venography were used to
confirm symptomatic DVT and were assessed centrally.
Deaths were considered to be due to VTE if they were
categorized as VTE-related or unexplained.
Safety outcomes concentrated on bleeding events and
included major bleeding events (MBE), incorporating
surgical-site bleeds, and clinically relevant (non-major)bleeding events (CRBE). All bleeding events were classi-
fied as described previously [5-7,13].
Type of anaesthesia
In these studies, general anaesthesia, spinal and/or epi-
dural (neuraxial) anaesthesia and peripheral nerve block
were used. For the post-hoc analyses, patients were clas-
sified as having received general or neuraxial anaesthesia
or a combination; the combination was defined as gen-
eral or neuraxial anaesthesia plus peripheral nerve block.
The type of anaesthesia used was recorded in the elec-
tronic case record form.
In patients who received neuraxial anaesthesia, the
recommendation was not to initiate the first dose of oral
therapy for a minimum of 2 hours after the catheter was
removed. Trial medication was stopped if patients had
an indwelling epidural catheter for pain relief post-
surgery [5-7].
Statistics
Subgroup analyses of the pooled data from the three
trials were performed to determine: (a) if the anaesthesia
technique used affected the study outcomes in the over-
all population across all treatment groups (without look-
ing into the different prophylactic therapies); and (b) if
the different anaesthesia techniques had an influence on
the efficacy and safety of 220 mg and 150 mg dabigatran
etexilate compared with enoxaparin.
The efficacy analysis was based on a modified
intention-to-treat population: all randomized patients
who were operated on received at least one dose of
study drug, and had evaluable adjudicated data on
major VTE or confirmed VTE-related death during
treatment. No imputation for missing data was made
in any of the analyses. The safety population comprised
all randomized patients who received at least one dose
of study treatment (either subcutaneous injection or
oral drug).
Event rates are expressed as numbers and percentages.
Anaesthesia types were compared by generating odds
ratios (OR; with 95% confidence intervals [CI]) in the
pooled population. For comparisons between dabigatran
etexilate and enoxaparin common OR were generated
using a fixed effects model and the 95% CI is given for
the total population in the absence of heterogeneity. In
this post-hoc explorative analysis, no correction for
multiplicity was applied, therefore p-values should be
interpreted with caution. SASW (version 8.2, SAS Insti-
tute Inc., Cary, NC, USA) was used to perform the stat-
istical calculations.
Results
The pooled safety population comprised 8062 patients. Of
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Figure 1 Flow diagram showing patients comprising the pooled safety population in this post-hoc analysis.
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received a combination (Figure 1). No neuraxial haema-
toma was observed in the 4212 patients receiving neurax-
ial anaesthesia, irrespective of treatment group.Effect of anaesthesia type in the overall population
The baseline characteristics of patients in each anaesthe-
sia subgroup in the overall population (dabigatran and
enoxaparin) were generally similar (Table 1). There were
minor differences in mean age, body mass index (BMI)
and creatinine clearance (CrCl) and in the proportions
of patients with a history of hypertension or smoking
(numerically lower in patients receiving neuraxial anaes-
thesia) and in those aged >75 years or with creatinine
clearance <50 mL/min (numerically lower in the generalTable 1 Baseline characteristics for the pooled study






Number of patients 2311 4212 1539
Female, n (%) 1406 (60.8) 2471 (58.7) 902 (58.6)
Mean age, years ± SD 64.4 ± 10.5 66.2 ± 9.7* 65.6 ± 10.2*
Mean BMI, kg/m2 ± SD 30.2 ± 5.9 28.8 ± 4.9* 30.1 ± 5.8
CrCl, mL/min
Median 86.3 82.4* 82.9*
Minimum 22.0 20.9 25.0
Maximum 295.7 289.6 231.6
Smoker or ex-smoker, n (%) 945 (40.9) 1483 (35.2)* 650 (42.2)
Hypertension, n (%) 1353 (58.5) 2203 (52.3)* 862 (56.0)
>75 years, n (%) 315 (13.6) 746 (17.7)* 266 (17.3)*
<50 CrCl, n (%) 156 (6.8) 341 (8.1) 126 (8.2)
>75 years or <50 CrCl, n (%) 371 (16.1) 870 (20.7)* 299 (19.4)*
SD, standard deviation; BMI, body mass index; CrCl, creatinine clearance.
*p< 0.05 when compared to general anaesthesia treatment arm.anaesthesia group) but given the large size of the cohorts
compared, even minor differences were statistically
significant.
The event rates observed with the different anaesthesia
types and OR for comparisons between groups are
shown in Table 2. The differences in efficacy and safety
outcomes between anaesthesia subgroups in the overall
population were small and not statistically significant,
except for a slightly higher rate of major VTE and VTE-
related mortality with general anaesthesia alone versus
neuraxial anaesthesia alone (OR 1.40, 95% CI 1.03–1.90,
p = 0.035).
Effect of anaesthesia type on the comparison between
dabigatran and enoxaparin
Statistical comparisons of the efficacy and safety of dabi-
gatran versus enoxaparin (OR with 95% CI) are given in
Figure 2. The absolute event rates observed with 220 mg
dabigatran etexilate, 150 mg dabigatran etexilate and
enoxaparin for the different types of anaesthesia are alsoTable 2 Effect of type of anaesthesia on outcomes: event
rates observed with the different types of anaesthesia in










MBE 1.2% 1.4% 1.2%
(27/2311) (59/4212) (19/1539)
MBE/CRBE 4.9% 5.6% 5.7%
(114/2311) (237/4212) (88/1539)
*Only significantly different odds ratio (general versus neuraxial): 1.40 (95%
confidence interval: 1.03–1.90, p = 0.035); all other comparisons are not
significant.

































































Figure 2 Comparison of 220 mg and 150 mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed
according to the type of anaesthesia: (A) major venous thromboembolism (VTE) and VTE-related mortality; (B) major bleeding events;
(C) major bleeding events plus clinically relevant bleeding events. Data are presented as the odds ratio with 95% confidence intervals.
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safety outcomes, 220 mg dabigatran etexilate was com-
parable to enoxaparin (OR ranged from 0.7 to 1.3 with
all 95% CIs crossing 1.0, showing no statistically signifi-
cant difference), regardless of the type of anaesthesia
used during surgery. Similarly, the type of anaesthesia
used during surgery did not affect the efficacy and safety
of 150 mg dabigatran etexilate compared to enoxaparin
(OR range: 0.7–1.5 with all 95% CIs crossing 1.0, show-
ing no statistically significant difference).
Effect of anaesthesia type in the individual treatment
groups
Table 3 includes the statistical comparison of event rates
in the neuraxial anaesthesia or combination anaesthesia
subgroups versus the general anaesthesia subgroup
within each treatment. There was no clear pattern in the
effect of anaesthesia type on rates of MBE; in fact, any
potential trends were reversed between the 220 mg and
150 mg dabigatran groups. Event rates appeared similar
across anaesthesia subgroups in the enoxaparin arm.
Discussion
In these studies the majority of patients received neurax-
ial anaesthesia, which is consistent with the trend in
clinical practice in Europe observed in the early 2000s
[8]. Compared with systemic analgesia, regional anal-
gesia can reduce post-operative pain, morphine con-
sumption, and nausea and vomiting; it may also reduce
blood loss after total hip arthroplasty [11]. In a more re-
cent trend, lower limb blocks are increasingly used for
analgesia for total joint arthroplasty and other surgeries,
in either a single-shot or continuous technique. These
provide effective analgesia and may be associated with
fewer adverse effects and potentially earlier mobilization
of patients [9,14,15]. It is perhaps surprising, therefore,
that only 19% of patients in our large patient population
(two European-based studies and one North American
based) received a combination of general or neuraxial
anaesthesia with a peripheral nerve block.
In our analysis of outcomes according to anaesthesia
type in the overall study population of more than 8000
patients (dabigatran and enoxaparin groups combined),
patients receiving general anaesthesia alone had a higher
rate of major thromboembolic events compared with
neuraxial anaesthesia alone, which just reached signifi-
cance (1.4-fold, 1.1% absolute risk difference; OR 1.40,
95% CI 1.03–1.90, p = 0.035); that is, patients receiving
neuraxial anaesthesia benefited from slightly lower rates
of VTE. However, there was no significant difference be-
tween general anaesthesia alone and the combination.
Due to the post-hoc nature of these analyses and the
multiplicity arising from several comparisons, findings
should be interpreted with caution. With regard to safetyoutcomes (MBE and MBE/CRBE), there was no signifi-
cant effect of anaesthesia type, despite the pooled groups
being large enough and there being adequate power to
find relevant differences. Other studies of the newer
anticoagulants found no difference between the rate of
DVT with general and neuraxial anaesthesia [16,17].
While a reduction in the risk of morbidity and mortality
(including VTE) with neuraxial anaesthesia has been
reported in several trials of general versus neuraxial an-
aesthesia for orthopaedic surgery [18-20], these studies
were undertaken before the widespread use of thrombo-
prophylaxis. Hence, this evidence is not corroborated by
more recent studies [21]. The value of meta-analyses has
been limited as they have included the older studies
[22-24]. However, a recent review of randomized con-
trolled trials since 1990 concluded that there was insuf-
ficient evidence from these trials, involving 1239
patients, to determine whether anaesthetic technique
influenced mortality, cardiovascular morbidity or the in-
cidence of VTE when using thromboprophylaxis [11].
In the pooled results of the RE-MODEL™, RE-NOVATEW
and RE-MOBILIZEW trials, major VTE and VTE-related
mortality occurred in 3.3% of the enoxaparin group,
3.0% of the 220 mg dabigatran etexilate group and 3.8%
of the 150 mg dabigatran etexilate group; MBE oc-
curred in 1.4%, 1.4% and 1.1%, respectively; and MBE/
CRBE in 5.0%, 5.6% and 5.6%, respectively. There were
no significant differences between dabigatran and enox-
aparin [25]. Our comparisons of dabigatran etexilate
with enoxaparin in the pooled data sets demonstrated
that the 220 mg dose of dabigatran etexilate, approved
for use in the majority of patients undergoing ortho-
paedic surgery, was as effective and safe as enoxaparin,
regardless of the type of anaesthesia used during sur-
gery. Similarly, 150 mg dabigatran etexilate showed no
statistically significant differences compared with enoxa-
parin regardless of anaesthesia type (Figure 2 shows that
all 95% CIs for the OR values all crossed 1.0).
In our comparison of the effect of anaesthesia type on
results within each treatment group, we observed a pos-
sible trend towards more effective prevention of major
VTE and VTE-related mortality when using either neur-
axial or combination anaesthesia as opposed to general
anaesthesia in the dabigatran groups. There was no clear
direction of effect of anaesthesia on MBE, and event
rates were similar across all anaesthesia types with enox-
aparin treatment. It is important to note, however, that
since this is a pooled analysis of studies that did not use
stratification in randomization with respect to type of
anaesthesia, the results should be interpreted with cau-
tion. Bias may have been introduced by differences in
the subpopulations. Although baseline characteristics of
patients in each anaesthesia subgroup generally appeared
to be similar (Table 1), some differences have reached
Table 3 Effect of type of anaesthesia on the efficacy and safety of dabigatran etexilate: event rates observed with the
different types of anaesthesia for each therapy
Outcome General anaesthesia Neuraxial anaesthesia Combination
Dabigatran etexilate 220 mg
Major VTE and VTE-related mortality 4.0% (23/578) 2.7% (29/1080) 2.7% (10/369)
OR (95% CI) versus general anaesthesia 0.67 (0.37–1.22) 0.67 (0.28–1.49)
MBE 0.9% (7/785) 1.7% (24/1379) 1.4% (7/497)
OR (95% CI) versus general anaesthesia 1.97 (0.82–5.43) 1.59 (0.47–5.34)
MBE/CRBE 4.8% (38/785) 5.9% (81/1379) 6.0% (30/497)
OR (95% CI) versus general anaesthesia 1.23 (0.82–1.87) 1.26 (0.74–2.12)
Dabigatran etexilate 150 mg
Major VTE and VTE-related mortality 5.1% (30/587) 3.2% (35/1082) 3.3% (13/395)
OR (95% CI) versus general anaesthesia 0.62 (0.37–1.06) 0.63 (0.30–1.27)
MBE 1.3% (10/781) 1.0% (14/1403) 0.8% (4/530)
OR (95% CI) versus general anaesthesia 0.78 (0.32–1.97) 0.59 (0.13–2.05)
MBE/CRBE 5.4% (42/781) 5.4% (76/1403) 6.6% (35/530)
OR (95% CI) versus general anaesthesia 1.01 (0.67–1.52) 1.24 (0.76–2.03)
Enoxaparin
Major VTE and VTE-related mortality 3.5% (20/566) 3.2% (37/1143) 3.1% (12/383)
OR (95% CI) versus general anaesthesia 0.91 (0.51–1.68) 0.88 (0.39–1.92)
MBE 1.3% (10/745) 1.5% (21/1430) 1.6% (8/512)
OR (95% CI) versus general anaesthesia 1.10 (0.49–2.62) 1.17 (0.40–3.31)
MBE/CRBE 4.6% (34/745) 5.6% (80/1430) 4.5% (23/512)
OR (95% CI) versus general anaesthesia 1.24 (0.81–1.93) 0.98 (0.55–1.74)
No statistically significant differences were observed between the dabigatran etexilate treatment groups and enoxaparin.
VTE, venous thromboembolism; OR, odds ratio; CI, confidence interval; MBE, major bleeding event; CRBE, clinically relevant bleeding event.
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addition, centres have different preferences to the type
of anaesthesia and these may have confounded results.
A potential difference between using an oral compound
versus a subcutaneous injected compound is the variability
of oral absorption, particularly in the first 6 hours after
surgery [26]. When general anaesthesia is used without re-
gional anaesthesia, post-operative pain following this kind
of major surgery has to be relieved with morphine, which
can induce nausea and vomiting leading to delayed ab-
sorption of oral compounds. Use of regional anaesthesia
reduces opioid consumption in the post-operative period
(and thus nausea and vomiting), resulting in more normal
absorption [26]. Although the recommendation is to initi-
ate therapy with dabigatran etexilate within 1–4 hours
after surgery using a half dose, if this is not possible (e.g.
due to vomiting) therapy should be initiated either later
the same day with a half dose or the following day using
the full dose. A post-hoc subgroup analysis of data on
delayed dosing versus initiation of therapy 1–4 hours
post-surgery from the RE-MODEL™ and RE-NOVATEW
trials (in the 220 mg dabigatran etexilate once-daily group)
found that delayed initiation of therapy did not affect theefficacy and safety of dabigatran etexilate for thrombopro-
phylaxis following orthopaedic surgery [27]. It is worth
noting that the majority of delays in initiation of therapy
were for logistical and other reasons, including late-day
surgery, organization of the ward and nursing error rather
than clinical reasons such as bleeding, drainage, catheters
or vomiting [27].
With regard to MBE, it is important to note that, in the
European studies, half the events seen with dabigatran
etexilate had an onset before the first dose had been given
(1–4 hours after surgery, according to the protocol)
[5,6,28]. In the European studies enoxaparin therapy was
initiated pre-surgery.
The 150 mg dabigatran etexilate dose was tested as an
alternative lower dose for use in certain patient groups
with an increased risk of bleeding, such as patients aged
over 75 years and those with moderate renal impairment
[28]. The summary of product characteristics recom-
mends the 150 mg dose for these patients, thus throm-
boprophylaxis can be tailored for these more fragile
individuals. Patients with pre-operative intermediate
renal impairment should have their renal function moni-
tored post-operatively, since deterioration of renal
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post-operative period. Patients with severe renal impair-
ment (creatinine clearance <30 mL/min) were excluded
from the studies.
In conclusion, neuraxial anaesthesia was the most
common technique, while combination with a peripheral
nerve block was limited to 19% of the operations. The
type of anaesthesia used during orthopaedic surgery did
not greatly affect the efficacy and safety outcomes in the
pooled population, although neuraxial anaesthesia
appeared to be associated with a slightly lower incidence
of VTE than general anaesthesia (OR 1.40). The efficacy
and safety of dabigatran etexilate was comparable to
enoxaparin in the overall study population and this re-
sult was maintained regardless of the type of anaesthesia.
Dabigatran etexilate provides an option for thrombopro-
phylaxis following orthopaedic surgery and has a good
balance between efficacy and safety, with the advantage
of oral administration and the ability to tailor the dose
for elderly and renally impaired patients.
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